Research programme: immunomodulators - Marker Therapeutics Inc/University of British Columbia
Latest Information Update: 24 Oct 2018
At a glance
- Originator
- Developer TapImmune
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 17 Oct 2018 TapImmune merged with Marker Therapeutics and changed its name to Marker Therapeutics Inc., while its subsidiary changed the name to Marker Cell Therapy
- 27 Feb 2004 Preclinical trials in Immunological disorders in USA (unspecified route)